Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Dopamine replacement therapy associated with increase in impulse control disorders among early Parkinson's disease patients

  • Busy schedules force young people to manage time well

  • Stroke researchers link ability to self-administer medication with memory loss

  • Young people of color mistrust police, legal system, report finds

  • Ethnoburbs: Segregation in suburbia

  • Notion of love can lead to greater acceptance of couples' rights

  • How genes, gender and environment influence substance abuse

  • Provider, parental assumptions on teen sex yield 'missed opportunities' for HPV vaccine

  • Poor health literacy poses risks for pacemaker, defibrillator patients

  • Genes determine traces that stress leaves behind on brains

  •